TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15170367
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg (once monthly)
Study: 9301991
Drug: Clarithromycin-omeprazole dual
Normalized name: AMOXICILLIN/CLARITHROMYCIN/OMEPRAZOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-omeprazole dual therapy
Study: 9301991
Drug: Omeprazole therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole therapy alone
Study: 24942409
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 1.4 ± 0.5 mg/kg
Study: 24942409
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (MPH) 52.4 ± 16.6 mg
Study: 21914270
Drug: Protein-free calf
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-free calf blood extract eye gel (3 times per day for three months)
Study: 21914270
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no drug treated group)
Study: 11174292
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium thiosulfate solution spray
Study: 11174292
Drug: Maalox (aluminum‐magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox (aluminum‐magnesium hydroxide gel)
Study: 8948741
Drug: Gelatine infusion
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine infusion with 3.5% urea bridges during normovolemic intentional hemodilution
Study: 31009034
Drug: Albuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2 actuations, 200 μg)
Study: 25551626
Drug: Hippotherapy (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (30 minutes twice weekly for 8 consecutive weeks)
Study: 19085221
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy session
Study: 19085221
Drug: Videotape about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape about art therapy
Study: 17045803
Drug: Concurrent motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent motor task (carrying a tray with marbles)
Study: 17045803
Drug: Concurrent motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent motor task (carrying a tray without marbles)
Study: 17045803
Drug: Walking alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking alone (no concurrent task)
Study: 15090936
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg/day for days 1-14; 100 or 200 mg/day for days 15-28)
Study: 11466245
Drug: Carteolol alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol alginate once daily
Study: 11466245
Drug: Standard carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard carteolol solution, twice daily
Study: 2846002
Drug: Corticosteroids (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (oral or parenteral)
Study: 30578392
Drug: Anlotinib therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib therapy
Study: 28245383
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (hydroxyurea plus IFN-alpha)
Study: 24929889
Drug: Progestogen-only pills
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only pills (POPs)
Study: 19580584
Drug: MEL 308
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL 308 nm once-weekly and oral vitamin E
Study: 19580584
Drug: MEL 308
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL 308 nm once-weekly combined with khellin 4% ointment and oral vitamin E
Study: 19580584
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E (control group)
Study: 17924873
Drug: 303 Algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 303 Algorithm group (self-titration dosing guideline)
Study: 15356670
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (herbal formulation containing ephedrine, caffeine, and other ingredients)
Study: 11368462
Drug: Placebo 5
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg
Study: 9529020
Drug: MAID chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAID chemotherapy (doxorubicin, dacarbazine, ifosfamide, and mesna)
Study: 9529020
Drug: MAID chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAID chemotherapy
Study: 2657839
Drug: Buspirone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (mean dose 29.5 mg/day)
Study: 2657839
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean dose 140 mg/day)
Study: 24535937
Drug: Decitabine +
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine + NY-ESO-1 vaccine + doxorubicin liposome chemotherapy
Study: 18793913
Drug: Sublingual triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual triazolam 0.25 mg
Study: 15728060
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of epidural saline
Study: 12503978
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 mg daily)
Study: 10841179
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg) plus Vitamin D (800 IU)
Study: 8853667
Drug: Immediate-release acetaminophen
Normalized name: acetaminophen Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release acetaminophen (IR APAP)
Study: 8422668
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human erythropoietin (r‐hEPO) administration (3000 IU, 12 cases; 6000 IU, 14 cases), three times a week
Study: 8422668
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human erythropoietin (r‐hEPO) administration
Study: 24525155
Drug: HTUPA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTUPA (25 mg bolus)
Study: 20116842
Drug: Interrupted sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted sedation (20 mg/mL propofol for 48 h, 1 mg/mL midazolam thereafter) (n=70, control group)
Study: 17573510
Drug: Posaconazole 800
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 800 mg/d, administered in divided doses for 34 to 365 days
Study: 17573510
Drug: Posaconazole treatment
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole treatment
Study: 17573510
Drug: Posaconazole treatment
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole treatment for >or= 12 months
Study: 12242060
Drug: Olanzapine (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (initiated at 2.5 mg/day, with increases allowed every 3 to 4 days up to a maximum of 15 mg/day)
Study: 8580279
Drug: Lintopride 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lintopride 0.1 mg/kg
Study: 8580279
Drug: Lintopride 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lintopride 0.3 mg/kg
Study: 8580279
Drug: Lintopride 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lintopride 0.5 mg/kg
Study: 2571184
Drug: Secretin and
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin and Somatostatin (combined infusion)
Study: 31378318
Drug: Cefiderocol 2-g
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 2-g dose (therapeutic)
Study: 31378318
Drug: Cefiderocol 4-g
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 4-g dose (supratherapeutic)
Study: 31378318
Drug: Moxifloxacin 400-mg
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400-mg oral dose
Study: 19856512
Drug: Chloroquine regimen
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine regimen group A (1200 mg total over 3 days: 600 mg on day 1, 300 mg on days 2 and 3)
Study: 19856512
Drug: Chloroquine regimen
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine regimen group B (1500 mg total over 3 days: 750 mg on day 1, 375 mg on days 2 and 3)
Study: 16480348
Drug: Anaesthetist-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthetist-administered propofol sedation
Study: 15333431
Drug: EDLA (extended-duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDLA (extended-duration local anesthetic) at concentrations of 6.25, 12.5, and 25 mg/mL
Study: 15333431
Drug: Aqueous bupivacaine
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous bupivacaine (5.0 mg/mL)
Study: 11140434
Drug: Micronised fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fluticasone propionate 0.1 mg, twice daily for 4 days
Study: 11140434
Drug: Micronised fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fluticasone propionate 1 mg, twice daily for 4 days
Study: 11140434
Drug: Micronised fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fluticasone propionate 10 mg, twice daily for 4 days
Study: 11140434
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 4 days
Study: 9062598
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (15 ml of 0.5% bupivacaine injected twice)
Study: 9062598
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 ml of 0.9% saline solution injected twice)
Study: 3481331
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 or 400mg twice daily)
Study: 3481331
Drug: Doxycycline (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100mg twice daily)
Study: 28784001
Drug: Maintenance tocolysis
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance tocolysis with tablet nifedipine for 12 days or up to 34 weeks of gestation.
Study: 18234355
Drug: Paroxetine or
Normalized name: paroxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine or citalopram treatment for 1 year
Study: 12859470
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia using an atomiser
Study: 10375948
Drug: Active sarcoidosis
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sarcoidosis treated with steroids
Study: 7076102
Drug: Nitrofurantoin macrocrystals
Normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin macrocrystals (100 mg every 12 hours for two days)
Study: 7076102
Drug: Trimethoprim/sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (160 mg and 800 mg respectively every 12 hours for two days)
Study: 27595687
Drug: CCTA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTA in combination with CTP
Study: 17669143
Drug: Propiverine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 20 mg
Study: 15498087
Drug: Pramlintide 60
Normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 60 microg three times daily (TID)
Study: 15498087
Drug: Pramlintide 60
Normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 60 microg four times daily (QID)
Study: 9572539
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (DS) 0.1% solution, 1 drop four times daily for 14 days
Study: 9572539
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (KT) 0.5% solution, 1 drop four times daily for 14 days
Study: 8113776
Drug: Day Hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day Hospital (DH) rehabilitation (27 hours of weekday treatment weekly)
Study: 8113776
Drug: Inpatient (INP)
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient (INP) rehabilitation (48 hours of scheduled treatment weekly)
Study: 2455331
Drug: Carbachol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbachol (0.25 mg s.c.)
Study: 2455331
Drug: Oral Carbachol
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Carbachol (6 or 12 mg/day for 2 weeks)
Study: 19483180
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg/day
Study: 11403727
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg/day
Study: 16325470
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose quinapril (10 mg/day)
Study: 11127501
Drug: Inhaling an
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaling an anti-cholinergic drug
Study: 8861087
Drug: Tibolone (Livial,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (Livial, 2.5 mg daily)
Study: 8861087
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (Premarin, 0.625 mg daily) + Medrogestone (Colpron, 2 x 5 mg daily for 12 days each month)
Study: 1298968
Drug: Sulodexide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (100 mg/die)
Study: 6723531
Drug: High-dosage recombinant
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 50 X 10(6) E/m2 as 30-minute infusion on 5 consecutive days four-weekly
Study: 6723531
Drug: High-dosage recombinant
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 20 X 10(6) E/m2 subcutaneously thrice weekly
Study: 27189282
Drug: COX‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitor (COX‐2i)
Study: 22307926
Drug: Intravenous hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyoscine butylbromide
Study: 22307926
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol + hyoscine butylbromide
Study: 17852629
Drug: 2.5% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% testosterone gel
Study: 16342345
Drug: DDDR pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDDR pacing and antiarrhythmic drugs
Study: 8907133
Drug: Levosimendan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.25 mg
Study: 8907133
Drug: Levosimendan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.5 mg
Study: 8907133
Drug: Levosimendan 4
Normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 4 mg
Study: 356707
Drug: High-dose pentazocine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pentazocine (0.9 mg/kg)
Study: 28174052
Drug: Expedited transfer
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited transfer to a cardiac arrest centre (CAC) for goal-directed therapy including access to immediate reperfusion
Study: 26194186
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation plus perioperative ECF chemotherapy
Study: 23585314
Drug: Nomogram 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram 1 (bolus of 80 U/Kg/h and initial infusion rate of 17 U/Kg/h)
Study: 23585314
Drug: Nomogram 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram 2 (bolus of 60 U/Kg, maximum of 4000 U, and initial infusion rate of 12 U/Kg/h, maximum of 900 U/h)
Study: 18376260
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole once per day (group A)
Study: 18376260
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg lansoprazole twice per day (group B)
Study: 12667306
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Isorel biotherapy (29 patients)
Study: 12667306
Drug: Only chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only chemotherapy (21 patients)
Study: 10894870
Drug: Thalidomide 800
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 800 mg (escalated to 1,200 mg)
Study: 10461824
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg
Study: 1465754
Drug: Inhaled bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bradykinin (8 mg/ml)
Study: 31801567
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1.5 g), Thiamine (100 mg), and Hydrocortisone (50 mg) given every 6 h for up to 16 doses
Study: 24462479
Drug: 12-session 12-step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12-session 12-step facilitation therapy (TSF)
Study: 23171020
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral azithromycin (10 mg/kg/d) plus allopurinol (10 mg/kg/d) for two months
Study: 23171020
Drug: Intramuscular Glucantime
Normalized name: Glucantim
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Glucantime (20 mg/kg of antimony daily for 20 days)
Study: 15565575
Drug: DCC method
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCC method for scoring estrogen receptor (ER)
Study: 7497685
Drug: Articulating spacer
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulating spacer with antibiotic-impregnated cement
Study: 1827368
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (Topicycline)
Study: 1827368
Drug: 5% benzoyl-peroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzoyl-peroxide gel
Study: 1827368
Drug: Oral oxytetracycline
Normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxytetracycline (250 mg twice daily)
Study: 7040493
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 mg, increased to a maximum of 10 mg daily)
Study: 7040493
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg, increased to a maximum of 400 mg daily)
Study: 31805932
Drug: Treatment costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment costs due to complications
Study: 27744016
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Group A)
Study: 15040805
Drug: conservative standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: conservative standard therapy
Study: 11847411
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% solution
Study: 31809325
Drug: Intravenous open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous open label placebo
Study: 20433733
Drug: Mechanical traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical traction with extension-oriented treatment approach
Study: 20433733
Drug: Extension-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension-oriented treatment approach without mechanical traction
Study: 16554199
Drug: Initial endodontic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial endodontic treatment
Study: 7892081
Drug: Combined schedule
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined schedule of inactivated polio vaccine followed by two doses of live attenuated oral polio vaccine
Study: 7892081
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated oral polio vaccine (three doses)
Study: 3258660
Drug: Conjugated polyribosyl
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated polyribosyl ribitol phosphate (PRP) vaccine
Study: 3258660
Drug: Unconjugated polyribosyl
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unconjugated polyribosyl ribitol phosphate (PRP) vaccine
Study: 30980421
Drug: Misoprostol/phenytoin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol/phenytoin gel treatment on two wounds
Study: 17032160
Drug: Manual Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Assisted Cognitive Treatment (MACT)
Study: 11066029
Drug: Mucolytic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucolytic medication
Study: 9337828
Drug: Exhalation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exhalation at an expiratory flow rate of 250 ml/min